Abstract

Obesity, defined as New World Syndrome, causes global health problems and big economic losses. Natural products have gained increasing importance because of their antiobesity potency. The genus Jurinea Cass. with approximately 200 described species worldwide has been traditionally used as a therapeutic agent for colic, fever, gout and rheumatism. The aim of this study was to analyze the volatile components, to determine phenolic compounds and to evaluate α-amylase, α-glucosidase, and lipase inhibitory activities of the endemic plant species Jurinea brevicaulis Boiss. The widely used solid-phase microextraction technique (SPME) was employed for Gas Chromatography-Mass Spectrometry (GC/MS) analysis of the volatile components. Quantitative analysis of phenolic compounds was performed using Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC). A total of 19 volatile components were specified and o-cymene (10.60 %), β-bisabolene (9.30 %), and sesquicineole (57.5 %) for different terpenes were described as major components. According to the RP-HPLC analysis, sinapic acid, p-coumaric acid and quercetin were determined for the species. IC50 values of the species were determined as 36.59 ± 2.37 μg/mL and 42.56 ± 2.83 μg/mL for α-amylase and α-glucosidase assays, respectively. IC50 value was found as 50.31 ± 3.75 μg/mL with the lipase inhibition analysis. In conclusion, it has been determined that J. brevicaulis included diverse volatile components, three phenolic compounds with antiobesity effect potential, which highlights J. brevicaulis as the up-and-coming candidate of natural product source to be used against obesity.